98518-10-6

Basic information

• Product Name: Benzyl oxopropyl mesylate
• Synonyms: Benzyl oxopropyl mesylate
• CAS NO: 98518-10-6
• Molecular Formula: C₁₁H₁₆O₄S
• Molecular Weight: 242.29146
• Mol File: 98518-10-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzyl oxopropyl mesylate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl oxopropyl mesylate(98518-10-6)
• EPA Substance Registry System: Benzyl oxopropyl mesylate(98518-10-6)

Safety Data

• Hazardous Substances Data: 98518-10-6(Hazardous Substances Data)

Upstream product

• 4799-68-2 3-benzyloxypropan-1-ol 
• 124-63-0 methanesulfonyl chloride 
• 100-44-7 benzyl chloride 
• 100-52-7 benzaldehyde 
• 772-01-0 2-phenyl-1,3-dioxane 

Downstream Products

• 744262-47-3 9-(3-benzyloxypropyl)adenine 
• 638563-86-7 12-(3-benzyloxypropyl)-6H,7H,13H-indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ne 
• 1309960-92-6 1-[3-(benzyloxy)propyl]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 188878-41-3 3-(benzyloxy)-N-methylpropan-1-amine 
• 615268-03-6 ethyl 2-(3-(benzyloxy)propoxy)acetate 
• 99701-65-2 6-(benzyloxy)hexan-2-one 
• 1167572-51-1 dibenzyl pentapropylene glycol 
• 1141781-16-9 2-(2-(3-(3-(benzyloxy)propoxy)phenoxy)ethyl)isoindoline-1,3-dione 

Relevant articles and documents

Self-assembling behaviour of chiral calamitic monoacrylates targeted for polymer stabilisation of polar smectic phases in chiral liquid crystals

The stabilisation and control of synclinic and anticlinic chiral liquid crystalline phases remain an actual and highlighted task. This work presents the design and mesomorphic properties of new chiral calamitic reactive mesogens, monoacrylates, based on biphenyl benzoate and phenyl biphenyl-4-carboxylate cores with reactive terminal groups placed far from the chiral chain. The compound's structures, compatible with the components of modern ferroelectric and antiferroelectric liquid crystalline mixtures, are confirmed by mass spectrometry (electron ionization) analysis and proton/carbon nuclear magnetic resonance. All the reactive mesogens possess the self-assembling, i.e. liquid crystalline behaviour with high tendency to create smectic phases in a broad temperature range, which was confirmed by a polarizing optical microscopy, differential scanning calorimetry and broad-band dielectric spectroscopy. Doping of advanced multicomponent mixtures possessing the chiral smectic phases by the designed monoacrylates with further cross-linking procedure, can be an effective and functional tool for stabilising ferroelectric and antiferroelectric phases in various states and hence, can allow the symmetrisation of the switching times in the modes employed surface stabilised geometry; this is a very highlighted task for optoelectronics. Moreover, an evident considerable tendency for thermal polymerisation of specific reactive mesogens can reduce the drawbacks of polymer stabilisation.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration

Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA1) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA1 agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA1 receptor agonist described so far (Emax = 118%, EC50 = 0.24 μM, KD = 19.6 nM; inactive at autotaxin and LPA2-6 receptors). This compound induces characteristic LPA1-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.

Convenient Continuous Flow Synthesis of N-Methyl Secondary Amines from Alkyl Mesylates and Epoxides

The first continuous flow process was developed to synthesize N-methyl secondary amines from alkyl mesylates and epoxides via a nucleophilic substitution using aqueous methylamine. A variety of N-methyl secondary amines were produced in good to excellent yields, including a number of bioactive compounds or their precursors. Up to 10.6 g (88% yield) of an N-methyl secondary amine was produced in 140 min process time. The amination procedure included an in-line workup, and the starting mesylate material was also produced in continuous flow from the corresponding alcohol. Finally, an in-line process combining the mesylate synthesis and nucleophilic substitution was developed.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof

Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.

2-AMINO-1,3,4-THIADIAZINE AND 2-AMINO-1,3,4-OXADIAZINE BASED ANTIFUNGAL AGENTS

The invention provides a compound which is a diazine of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt thereof, for use as an antifungal agent: (I) wherein X, N', C', A and E are as defined herein. The invention also provides a compound of Formula (I) as defined herein.

Method for synthesizing azanol

The invention relates to a hydroxylamine synthesis method. The hydroxylamine synthesis method comprises the following steps: (A) enabling alcohol to react with alkyl sulfonyl halide in the presence of an acid-binding agent to obtain sulphonate; (B) enabling the obtained sulphonate in the step (A) to react with N-hydroxycyclodiimide in the presence of alkali to generate alkylate of the N-hydroxycyclodiimide; and (C) enabling the alkylate obtained in the step (B) to react with an aminolysis reagent or a hydrazinolysis reagent to obtain the hydroxylamine. The method is high in yield and suitable for large-scale industrial hydroxylamine synthesis.

The Role of Ligand Topology in the Decomplexation of Luminescent Lanthanide Complexes by Dipicolinic Acid

In this study, we present the aqueous solution behavior of two luminescent lanthanide antenna complexes (Eu3+?1, Dy3+?9) with different ligand topologies in the presence of dipicolinic acid (DPA, pyridine-2,6-dicarboxylic acid). Macrocyclic (1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, DO3A, 9) and acyclic (1,4,7-triazaheptane-1,1,7,7-tetraacetic acid, DTTA, 1) ligands have been selected to form a ratiometric pair in which Dy3+?9 acts as a reference and Eu3+?1 acts as a probe for the recognition of DPA. The pair of luminescent complexes in water reveals the capability to work as a DPA luminescent sensor. The change of emission intensity of Eu3+ indicates the occurrence of a new sensitization path for the lanthanide cation through excitation of DPA. NMR evidence implies the presence of free 1 and mass spectrometry shows the formation of emitting [EuDPA2]? as a result of a ligand exchange reaction.

Discovery of a 5 H-benzo[4,5]cyclohepta[1,2-b ]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer

c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes. In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a number of approaches to disrupt aberrant c-Met signaling. Screening efforts identified a unique class of 5H-benzo[4,5] cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1. Subsequent SAR studies led to the development of 81 (MK-2461), a potent inhibitor of c-Met that was efficacious in preclinical animal models of tumor suppression. In addition, biochemical studies and X-ray analysis have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase. This report details the development of 81 and provides a description of its unique biochemical properties.